Maggie So

We recently identified a compound that kills N. gonorrhoeae in vitro and in a mouse model of lower genital tract infection; we know the mechanism, and we have patented this technology. We aim to develop this compound as an anti-infective for N. gonorrhoeae, using an approach that should receive FDA approval relatively quickly (in brief, by incorporating this compound into personal lubricants/vaginal gels). Indeed, our in vitro results show that the formations kill the pathogen. We seek funds to develop this project further, i.e., moving the study to the mouse model, and ultimately to humans.